CMPX vs. ARDX, EVO, ETNB, OCUL, GPCR, IOVA, CALT, AUPH, GYRE, and SNDX
Should you be buying Compass Therapeutics stock or one of its competitors? The main competitors of Compass Therapeutics include Ardelyx (ARDX), Evotec (EVO), 89bio (ETNB), Ocular Therapeutix (OCUL), Structure Therapeutics (GPCR), Iovance Biotherapeutics (IOVA), Calliditas Therapeutics AB (publ) (CALT), Aurinia Pharmaceuticals (AUPH), Gyre Therapeutics (GYRE), and Syndax Pharmaceuticals (SNDX). These companies are all part of the "pharmaceutical products" industry.
Compass Therapeutics vs.
Ardelyx (NASDAQ:ARDX) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, community ranking, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations.
Compass Therapeutics has a net margin of 0.00% compared to Ardelyx's net margin of -11.73%. Ardelyx's return on equity of -24.87% beat Compass Therapeutics' return on equity.
Ardelyx received 500 more outperform votes than Compass Therapeutics when rated by MarketBeat users. However, 77.08% of users gave Compass Therapeutics an outperform vote while only 67.46% of users gave Ardelyx an outperform vote.
Ardelyx has higher revenue and earnings than Compass Therapeutics. Ardelyx is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Ardelyx had 2 more articles in the media than Compass Therapeutics. MarketBeat recorded 4 mentions for Ardelyx and 2 mentions for Compass Therapeutics. Ardelyx's average media sentiment score of 0.70 beat Compass Therapeutics' score of 0.44 indicating that Ardelyx is being referred to more favorably in the media.
58.9% of Ardelyx shares are held by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are held by institutional investors. 5.9% of Ardelyx shares are held by company insiders. Comparatively, 28.5% of Compass Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Ardelyx has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500. Comparatively, Compass Therapeutics has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500.
Ardelyx currently has a consensus target price of $10.95, indicating a potential upside of 122.11%. Compass Therapeutics has a consensus target price of $11.38, indicating a potential upside of 471.61%. Given Compass Therapeutics' higher probable upside, analysts clearly believe Compass Therapeutics is more favorable than Ardelyx.
Summary
Ardelyx beats Compass Therapeutics on 11 of the 19 factors compared between the two stocks.
Get Compass Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CMPX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Compass Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CMPX) was last updated on 3/29/2025 by MarketBeat.com Staff
